First Results of DLBCL Patients Treated With Car‐t Cells and Enrolled in Descar‐t Registry, a French Real‐life Database for Car‐t Cells in Hematologic Malignancies

Abstract

and to guide post-CAR-T management in lymphoma. While patients achieving early DS 1-2 remission show excellent long-term outcomes, patients with DS 3-4 might benefit from combination approaches within clinical trials to increase the chance of ongoing remission.Patients with DS 5 response had dismal outcome in our cohort and should be regarded primary treatment failure for which early therapeutic intervention might be warranted.

A national service for delivering CD19 CAR‐Tin large B‐cell lymphoma – The UK real‐world experience

“…For axi-cel, no difference in high-grade ICANS between ZUMA-1 and the two large US RW cohorts was seen, but there was a lower rate in European datasets including ours. 5,6,15,18 Similar to the German RW cohort, 9 we observed ongoing NRM events beyond month 1, with a 12-month rate of 7%, mainly caused by complications from long-term cytopenia and infections (6/21 were COVID19-related deaths).…”

“…For tisa‐cel, a consistently low rate of severe CRS and ICANS was observed across different RW datasets, 8,11,9 in line with the more permissive use of tocilizumab and corticosteroids in daily practice. For axi‐cel, no difference in high‐grade ICANS between ZUMA‐1 and the two large US RW cohorts was seen, but there was a lower rate in European datasets including ours 5,6,15,18 . Similar to the German RW cohort, 9 we observed ongoing NRM events beyond month 1, with a 12‐month rate of 7%, mainly caused by complications from long‐term cytopenia and infections (6/21 were COVID19‐related deaths).…”

“…Since a significant number of eligible patients, 26% in our cohort, fail to proceed with CAR-T treatment, results from the infused ("modified ITT") population will inherently over-estimate the clinical benefit of CAR-T and thus be of limited value for upfront decision-making. ITT outcomes are not published for most CAR-T datasets, apart from the French RW experience and the JULIET trial (drop-out rates of 15% and 33%, respectively), 4,15 but should be the benchmark to compare CAR-T against alternative treatments. The unique CAR-T approval system in the UK through a central, independent panel not only provides transparent treatment access, but also ITT outcomes from a consecutive national cohort.…”

Current options and future perspectives in the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma

“… 55 Recently, data from the French national registry DESCAR-T have been presented. 57 In total, 463 patients who received commercial CAR T-cells at 14 French centers were included in this analysis. Median age was 63 years and patients received a median number of three prior lines of therapy.…”

Car T Cell Therapy. A New Milestone in the Treatment of B Cell Lymphomas

“…Vol. 2(1), [21][22][23][24][25][26][27][28][29][30][31][32][33]2022 SCEND-CLL-044 is assessing CAR-T cell therapy in chronic lymphocytic leukemia/small lymphocytic lymphoma (NCT03331198).…”